Market Spotlight: Myelofibrosis (MF)
Market Spotlight: Myelofibrosis (MF)
$1,318.00
Datamonitor Healthcare estimates that in 2019, there were 49,500 prevalent cases of myelofibrosis in adults aged 50 years and older worldwide, and forecasts that number to increase to 60,700 prevalent cases by 2028.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Myelofibrosis (MF) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2019, there were 49,500 prevalent cases of myelofibrosis in adults aged 50 years and older worldwide, and forecasts that number to increase to 60,700 prevalent cases by 2028.
- Bristol Myers Squibb’s Inrebic, Incyte’s Jakafi, and CTI BioPharma’s Vonjo are the only marketed drugs for myelofibrosis. These drugs are administered via the oral route.
- The majority of industry-sponsored drugs in active clinical development for myelofibrosis are in Phase II. Therapies in development for myelofibrosis focus on a wide variety of targets. The majority of the pipeline drugs are administered via the oral route.
- High-impact upcoming events for drugs in the myelofibrosis space comprise topline Phase I/II trial results for Jakafi; topline Phase IIa trial results for GB2064; and topline Phase III trial results for Reblozyl, Jakafi, navitoclax, imetelstat, pelabresib, INCB057643, INCB000928, and Vonjo.
- The overall likelihood of approval of a Phase I hematologic asset is 8.3%, and the average probability a drug advances from Phase III is 58.5%. Drugs, on average, take 9.6 years from Phase I to approval, compared to 9.7 years in the overall oncology space.
- The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for myelofibrosis have been in the early and mid-phases of development, with 85% of trials in Phase I–II, and only 15% in Phase III–IV.
- The US has a substantial lead in the number of myelofibrosis clinical trials globally. Germany and Italy lead the major European markets, while South Korea has the top spot in Asia.
- Novartis has the highest number of completed clinical trials for myelofibrosis, with 14 trials.
- Incyte leads industry sponsors with the highest overall number of clinical trials for myelofibrosis, closely followed by Novartis.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
9 TREATMENT
9 Anemia
9 Splenomegaly
10 Curative treatment
12 EPIDEMIOLOGY
15 MARKETED DRUGS
17 PIPELINE DRUGS
24 RECENT EVENTS AND ANALYST OPINION
24 Momelotinib for Myelofibrosis (January 25, 2022)
25 Bomedemstat for Myelofibrosis (December 5, 2020)
27 Momelotinib for Myelofibrosis (December 5, 2020)
28 Pelabresib for Myelofibrosis (December 5, 2020)
30 KEY UPCOMING EVENTS
31 KEY REGULATORY EVENTS
31 CTI Bites Off Big Chunk Of Myelofibrosis Market With Vonjo Approval
31 BioCryst & Celgene Suffer English Funding Setback For Rare Disease Drugs
32 PROBABILITY OF SUCCESS
33 LICENSING AND ASSET ACQUISITION DEALS
33 Hansoh Licenses Cytopenia Candidate From Keros
33 Merck’s $11.5bn Acceleron Buy Partially Fills Future Keytruda Revenue Gap
33 CTI BioPharma Enters Into Royalty Sales Agreement With DRI Healthcare
33 Sierra Oncology Signs Global License Agreement with AstraZeneca for AZD5153
34 MorphoSys Hits Refresh Button On Pipeline With Constellation Buy
34 Nippon Shinyaku Licenses Menarini’s Tagraxofusp For Japan
35 REVENUE OPPORTUNITY
36 CLINICAL TRIAL LANDSCAPE
37 Sponsors by status
38 Sponsors by phase
39 Recent events
40 BIBLIOGRAPHY
41 APPENDIX
LIST OF FIGURES
14 Figure 1: Trends in prevalent cases of myelofibrosis, 2019–28
17 Figure 2: Overview of pipeline drugs for myelofibrosis in the US
17 Figure 3: Pipeline drugs for myelofibrosis, by company
18 Figure 4: Pipeline drugs for myelofibrosis, by drug type
18 Figure 5: Pipeline drugs for myelofibrosis, by classification
25 Figure 6: Momelotinib for Myelofibrosis (January 25, 2022): Phase III – MOMENTUM
30 Figure 7: Key upcoming events in myelofibrosis
32 Figure 8: Probability of success in the hematologic pipeline
36 Figure 9: Clinical trials in myelofibrosis
36 Figure 10: Top 10 drugs for clinical trials in myelofibrosis
37 Figure 11: Top 10 companies for clinical trials in myelofibrosis
37 Figure 12: Trial locations in myelofibrosis
38 Figure 13: Myelofibrosis trials status
39 Figure 14: Myelofibrosis trials sponsors, by phase
LIST OF TABLES
13 Table 1: Prevalent cases of myelofibrosis, 2019–28
16 Table 2: Marketed drugs for myelofibrosis
19 Table 3: Pipeline drugs for myelofibrosis in the US
24 Table 4: Momelotinib for Myelofibrosis (January 25, 2022)
26 Table 5: Bomedemstat for Myelofibrosis (December 5, 2020)
27 Table 6: Momelotinib for Myelofibrosis (December 5, 2020)
28 Table 7: Pelabresib for Myelofibrosis (December 5, 2020)
35 Table 8: Historical global sales, by drug ($m), 2016–20
35 Table 9: Forecasted global sales, by drug ($m), 2022–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Market Spotlight: Hypogonadism 
Sign up to the